ReviewTrends in pharmacological sciences2022
Circadian clock-based therapeutics in chronic pulmonary diseases.
Review in Trends in pharmacological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 13 citations in OpenAlex.
- PER1-related inflammatory signaling links night shift exposure to lower lung function in coal miners.iScience · 2026Article
- Circadian clock regulation in lung health and disease: molecular mechanisms and therapeutic opportunities.EXCLI journal · 2026Review
- Perturbation of the circadian clock in chronic diseases involving organ fibrosis.The Journal of clinical investigation · 2025Review
- A network of pro-inflammatory genes repressed by clock signalling in bronchial epithelium.ERJ open research · 2025Article
- Circadian clock gene expression: a key player in inflammation underlying chronic lung disease?ERJ open research · 2025Article
- The Circadian Rhythm of Asthma Immune Metabolism.Journal of immunology research · 2025Review
- Histone lactylation-ROS loop contributes to light exposure-exacerbated neutrophil recruitment in zebrafish.Communications biology · 2024Article
- House dust mite and Th2 cytokine-mediated epithelial barrier dysfunction attenuation by KL001 in 16-HBE cells.Tissue barriers · 2024Article
- Integrated bioinformatics and interaction analysis to advance chronotherapies for mental disorders.Frontiers in pharmacology · 2024Article
- Article
- Rev-erbα agonists suppresses TGFβ1-induced fibroblast-to-myofibroblast transition and pro-fibrotic phenotype in human lung fibroblasts.Biochemical and biophysical research communications · 2023Article
- IsAmerican journal of respiratory and critical care medicine · 2023Article
- Circadian regulation of pulmonary disease: the importance of timing.Clinical science (London, England : 1979) · 2023Review
- Regulating the Clock: REV-ERB Agonists as Promising Therapeutic Agents.GEN biotechnology · 2023Article
- Circadian clock molecule REV-ERBα regulates lung fibrotic progression through collagen stabilization.Nature communications · 2023Article
- Current Perspective on the Role of the Circadian Clock and Extracellular Matrix in Chronic Lung Diseases.International journal of environmental research and public health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The circadian clock is the biochemical oscillator that orchestrates the observable circadian rhythms in physiology and behavior. Disruption of the circadian clock in the lungs during chronic pulmonary diseases is considered one of the key etiological risk factors that drive pathobiology. Preclinical studies support that pharmacological manipulation of the circadian clock is a conceivable approach for the development of novel clock-based therapeutics. Despite recent advances, no effort has been undertaken to integrate novel findings for the treatment and management of chronic lung diseases. We, therefore, recognize the need to discuss the candidate clock genes that can be potentially targeted for therapeutic intervention. Here, we aim to create the first roadmap that will advance the development of circadian- clock-based therapeutics that may provide better outcomes in treating chronic pulmonary diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.